Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents
(Last updated:5/7/2013; last reviewed:5/7/2013)
Syphilis is associated with increased risk of sexual acquisition and transmission of HIV.1,2
In recent years, there has been a resurgence of the disease in men in several U.S. cities and in Western Europe (http://www.cdc.gov/std/stats
Although coexistent HIV infection, particularly in the advanced stages, may modify the diagnosis, natural history, or management of Treponema pallidum
infection, the principles of syphilis management are the same for persons with and without coexistent HIV infection.9-13
The effect of coexistent HIV on the protean manifestations of syphilis have been documented in multiple case reports and small case series, but in only a limited number of large studies. Some studies suggest that HIV infection may shift the clinical manifestations of syphilis, making clinical lesions more apparent, and may accelerate progression of syphilitic disease.10,11,14,15
Early syphilis in HIV-infected patients also may cause a transient decrease in CD4 T-lymphocyte (CD4) count and increase in HIV viral load that improves with recommended syphilis treatment regimens.16-20
Primary syphilis commonly manifests as a single painless nodule at the site of contact that rapidly ulcerates to form a classic chancre; in HIV-infected patients, however, multiple or atypical chancres occur and primary lesions may be absent or missed.10,21
Progression to secondary syphilis typically follows 2 to 8 weeks after primary inoculation. Although more rapid progression or severe disease can occur in HIV-infected patients with advanced immunosuppression, the clinical manifestations are similar to those in HIV-uninfected individuals. The manifestations of secondary syphilis involve virtually all organ systems. The most common manifestations—macular, maculopapular, papulosquamous, or pustular skin lesions—can involve the palms and soles and be accompanied by generalized lymphadenopathy, fever, malaise, anorexia, arthralgias, and headache.11,12,19
Condyloma lata (moist, flat, papular lesions in warm intertrigenous regions) can occur and may resemble human papillomavirus infection. Lues maligna is a rare manifestation of secondary syphilis, characterized by papulopustular skin lesions that evolve into ulcerative lesions with sharp borders and a dark central crust.22
Secondary syphilis, especially when associated with symptomatic early neurosyphilis, can resemble acute primary HIV infection. Constitutional symptoms, along with nonfocal central nervous system (CNS) symptoms and cerebrospinal fluid (CSF) abnormalities such as lymphocytic pleocytosis with a mildly elevated CSF protein, are common to both secondary syphilis and acute primary HIV infection.14,15,21,23-26
Signs and symptoms of secondary syphilis can persist from a few days to several weeks before resolving and evolving to latent or later stages.
Latent syphilis lacks overt clinical signs and symptoms, but relapse of manifestations of secondary syphilis can occur, most commonly during the first year after infection. Manifestations of tertiary syphilis generally include cardiovascular syphilis and gummatous syphilis or a slowly progressive disease that can affect any organ system. Neurosyphilis can occur at any stage of syphilis and manifest in varied clinical presentations, such as cranial nerve dysfunction, stroke, meningitis, acute or chronic change in mental status, loss of vibration sense, and auditory or ophthalmic abnormalities. Manifestations of symptomatic neurosyphilis in HIV-infected patients are similar to those in individuals who are not HIV infected. However, clinical manifestations of neurosyphilis, such as concomitant uveitis and meningitis, may be more common in HIV-infected persons.14,15,26-28
Darkfield microscopy and tests to detect T. pallidum
in lesion exudates or tissue (biopsy with silver stain) are definitive for diagnosing early syphilis, although no T. pallidum
direct detection tests are commercially available. A presumptive serologic diagnosis of syphilis is possible based upon non-treponemal tests (i.e., Venereal Disease Research Laboratory [VDRL] and rapid plasma reagin [RPR]) and treponemal tests (i.e., fluorescent treponemal antibody absorbed [FTA-ABS], T. pallidum
particle agglutination [TP-PA], enzyme immunoassays [EIAs], and chemiluminescence immunoassays [CIA]).
Serologic diagnosis of syphilis traditionally has involved screening for non-treponemal antibodies with confirmation of reactive tests by treponemal-based assays.19,29
Recently, some laboratories have initiated a testing algorithm using EIA or CIA as a screening test, followed by a reflex-quantitative, non-treponemal test if the EIA or CIA is positive. This latter strategy may identify those with previously treated syphilis infection more often than those with untreated infection.30
In persons with a positive treponemal screening test and a negative reflex-quantitative, non-treponemal test, the laboratory should perform a second treponemal test (based on different antigens from the initial test) to confirm the results of the positive initial treponemal test. If a second treponemal test is positive, an assessment is needed of current sexual risk factors and prior syphilis treatment. Physical examination should be performed to assess for evidence of syphilis, especially primary disease. Patients with suspected primary syphilis should be empirically treated and retested with a non-treponemal test in several weeks (if initial non-treponemal test was non-reactive) to confirm the diagnosis. Persons with discordant sera (reactive EIA/CIA and non-reactive, non-treponemal test) and a reactive TP-PA assay should be treated for late-latent syphilis if past treatment cannot be confirmed. If the second treponemal test is negative, no treatment is indicated.19,31
In the absence of neurologic signs or symptoms, risk of neurosyphilis is low in patients with a reactive treponemal test and a non-reactive, non-treponemal test;32
examination of CSF is not recommended.
Early-stage disease (i.e., primary, secondary, and early-latent syphilis) in HIV-infected patients is confirmed with the same diagnostic tests used in those who are not infected with HIV: darkfield microscopy of a mucocutaneous lesion and standard serologic tests. Results with VDRL and RPR may be higher, lower, or delayed in HIV-infected versus HIV-uninfected patients with early-stage syphilis.33-37
No data indicate that treponemal tests perform differently among HIV-infected patients compared with HIV-uninfected patients,38
although uncommon, false-negative serologic tests for syphilis can occur in both HIV-uninfected and HIV-infected patients with documented T. pallidum
Therefore, if serologic tests do not confirm the diagnosis of suspected syphilis, other diagnostic procedures, such as repeat serology in 2 to 4 weeks, exclusion of prozone phenomenon, biopsy, or darkfield examination, should be pursued. By definition, persons with latent syphilis have serological evidence of syphilis in the absence of clinical manifestations. Early-latent syphilis is defined as evidence of infection <1 year; late-latent syphilis is evidence of infection for >1 year after acquisition of syphilis or latent infection of unknown duration. Diagnostic testing recommended for detection of late-stage syphilis (i.e., cardiovascular and gummatous syphilis) in HIV-infected patients is the same as in patients who are not infected with HIV.19
All persons with syphilis and signs or symptoms suggesting neurologic disease (e.g., cranial nerve dysfunction, meningitis, stroke, alteration in mental status, auditory or ophthalmic abnormalities) warrant evaluation for neurosyphilis and for ocular or otic syphilis if ophthalmic or auditory symptoms are present. CSF abnormalities (i.e., elevated protein and mononuclear pleocytosis) are common in early syphilis and in patients with HIV infection, even those with no neurologic symptoms. There is no evidence that the clinical and prognostic significance of such CSF abnormalities differs between HIV-infected and -uninfected patients with primary, secondary, or early-latent syphilis.
CSF examination should be performed in patients who have neurologic, auditory, or ophthalmic signs (e.g., iritis, uveitis) or symptoms, active tertiary syphilis, or serologic treatment failure. Several studies have demonstrated that in HIV-infected patients with syphilis, clinical and CSF abnormalities consistent with neurosyphilis are associated with CD4 counts ≤350 cells/mm3
alone or in combination with RPR titers ≥1:32..25,26,39,40
Unless neurologic symptoms are present, however, CSF examination in this setting has not been associated with improved clinical outcomes. The risk of later developing clinical neurosyphilis and the benefits of a CSF examination in this circumstance are unknown.
Laboratory testing is useful in supporting the diagnosis of neurosyphilis, but no single test can be used to diagnose it. In patients who are not HIV infected, CSF examination supports diagnosis of neurosyphilis, which may indicate mild mononuclear pleocytosis (6–200 cells/mm3
), normal or mildly elevated protein concentration, or a reactive (CSF-VDRL).19,25,26
CSF-VDRL is specific but not sensitive, and a reactive test establishes the diagnosis of neurosyphilis, but a non-reactive test does not exclude it. In comparison, CSF FTA-ABS is less specific than CSF-VDRL but highly sensitive. Calculated indices (T. pallidum
hemaglutination assay index) are of limited value in establishing the diagnosis of neurosyphilis. Polymerase-chain-reaction-based diagnostic methods are not currently recommended as diagnostic tests for neurosyphilis. A reactive CSF-VDRL and a CSF white blood cell (WBC) count >10 cells/mm3
support the diagnosis of neurosyphilis; in the absence of other abnormalities, elevation in CSF protein concentrations should not be used as the sole diagnostic criterion. Therefore, the laboratory tests used to support the diagnosis of neurosyphilis depend on various combinations of reactive serologic tests, CSF cell count and protein, and a reactive CSF-VDRL with or without clinical manifestations.
Establishing the diagnosis of neurosyphilis can be more difficult in patients with HIV infection because HIV infection itself may be associated with mild mononuclear CSF pleocytosis (6–15 cells/mm3
). Using a higher CSF WBC cutoff of >20 WBC/mm3
may improve the specificity of neurosyphilis diagnosis in HIV-infected patients.41
CSF FTA-ABS testing in HIV-uninfected persons suggests that the CSF FTA-ABS test is less specific for neurosyphilis than the CSF-VDRL but is highly sensitive.19,42
Thus, the use of this test may be considered in HIV-infected patients.
The resurgence of syphilis in patients with HIV infection in the United States underscores the importance of primary prevention of syphilis in this population, which should begin with routine discussion of sexual behaviors. Health care providers should discuss client-centered risk reduction messages and provide specific actions that can reduce the risk of acquiring sexually transmitted diseases and of transmitting HIV infection.19,43-47
Routine serologic screening for syphilis is recommended at least annually for all HIV-infected patients who are sexually active, with more frequent screening (every 3–6 months) for those who have multiple partners, unprotected intercourse, sex in conjunction with illicit drug use, or use methamphetamines (or whose partners participate in such activities).19,48-50
The occurrence of syphilis in an HIV-infected individual is an indication of high-risk behavior and should prompt intensified counseling messages and strong consideration of referral for behavioral intervention. Patients undergoing screening or treatment for syphilis also should be evaluated for all common sexually transmitted diseases such as chlamydia and gonorrhea at anatomic sites of exposure.19,51
The same measures that apply to preventing exposure apply to preventing disease. Studies in the pre-HIV era demonstrated that approximately one-third of the sex partners of patients who have infectious syphilis will develop syphilis within 30 days of exposure, and empiric treatment of incubating syphilis will prevent the development of disease in those who are exposed.52-55
Those exposed sexually to a patient with syphilis in any stage should be evaluated clinically and serologically and treated presumptively with regimens outlined in current recommendations.19
Specifically, individuals who were exposed within the 90 days preceding diagnosis of primary, secondary, or early-latent syphilis in a sex partner may be infected even if they are seronegative. Therefore, they should be treated presumptively (AII
). Individuals exposed >90 days before diagnosis of primary, secondary, or early-latent syphilis in a sex partner should be treated presumptively if serologic test results are not available immediately and the opportunity for follow-up is uncertain (AIII
Management of syphilis in HIV-infected patients is similar to that in individuals who are HIV-uninfected.13,19,34
Most HIV-infected patients respond appropriately to standard treatment. Closer follow-up is recommended, however, because rates of serologic treatment failure may be higher in those who are HIV infected and they may be at increased risk of neurologic complications.15,56,57
Penicillin remains the treatment of choice for syphilis regardless of a patient’s HIV status. HIV-infected patients with early-stage (primary, secondary, or early-latent) syphilis should receive a single intramuscular (IM) injection of 2.4 million units of benzathine penicillin G (AII
The available data demonstrate that high-dose amoxicillin given with probenecid in addition to benzathine penicillin G in early syphilis is not associated with improved clinical outcomes.34
Patients with a penicillin allergy whose compliance or follow-up cannot be ensured should be desensitized and treated with benzathine penicillin (AIII
). The efficacy of alternative non-penicillin regimens in HIV-infected patients with early syphilis has not been evaluated sufficiently to warrant their use as first-line treatment.
Regardless of HIV infection status, use of any alternative penicillin treatment regimen should be undertaken only with close clinical and serologic monitoring. Several retrospective studies support use of doxycycline, 100 mg twice daily, to treat early syphilis (BII
); however, the majority of the patients were HIV uninfected.58,59
Limited clinical studies suggest that ceftriaxone, 1 g daily either IM or intravenously (IV) for 10 to 14 days, is effective for treating early syphilis (BII
), but the optimal dose and duration of therapy have not been defined.60
A single 2-g oral dose of azithromycin is effective for treating early syphilis;61-63
however T. pallidum
chromosomal mutations associated with azithromycin resistance and treatment failures have been reported and are more common in men who have sex with men (MSM).64-69
Azithromycin treatment has not been well studied in HIV-infected patients with early syphilis and it should be used with caution in instances when treatment with penicillin or doxycycline is not feasible (BII
). Azithromycin should not be used
in MSM or in pregnant women (AII
In HIV-infected patients with late-latent syphilis and no signs or symptoms of neurosyphilis, treatment with 3 weekly IM injections of 2.4 million units benzathine penicillin G is recommended (AII
). Alternative therapy with doxycycline, 100 mg by mouth twice a day for 28 days, has not been sufficiently evaluated in HIV-infected patients to warrant use as first-line treatment (BIII
). Limited clinical studies and biologic and pharmacologic evidence suggest that ceftriaxone may be effective; however, the optimal dose and duration of therapy have not been determined.70,71
If the clinical situation requires use of an alternative to penicillin, treatment should be undertaken with close clinical and serologic monitoring.
HIV-infected patients with clinical evidence of late-stage (tertiary) syphilis (cardiovascular or gummatous disease) should have CSF examination to rule out neurosyphilis before therapy is initiated. Recommended treatment of late-stage syphilis is 3 weekly IM injections of 2.4 million units benzathine penicillin G (AII
However, the complexity of tertiary syphilis management is beyond the scope of these guidelines and health care providers are advised to consult an infectious disease specialist.
HIV-infected patients diagnosed with neurosyphilis or ocular or otic syphilis should receive IV aqueous crystalline penicillin G, 18 to 24 million units daily, administered 3 to 4 million units IV every 4 hours or by continuous infusion for 10 to 14 days (AII
) or procaine penicillin, 2.4 million units IM once daily plus probenecid 500 mg orally 4 times a day for 10 to 14 days (BII
HIV-infected patients who are allergic to sulfa-containing medications should not be given probenecid because of potential allergic reaction (AIII
Because neurosyphilis treatment regimens are of shorter duration than those used in late-latent syphilis, 2.4 million units benzathine penicillin IM once per week for up to 3 weeks after completion of neurosyphilis treatment can be considered to provide a comparable duration of therapy (CIII
Desensitization to penicillin is the preferred approach to treating neurosyphilis in patients who are allergic to penicillin. However, limited data indicate that ceftriaxone (2 g daily IV for 10–14 days) may be an acceptable alternative regimen (BII
Other alternative regimens for neurosyphilis have not been evaluated adequately. Syphilis treatment recommendations are also available in the 2010 Centers for Disease Control and Prevention STD Treatment Guidelines.19
Special Considerations with Regard to Starting ART
There are no special considerations regarding the initiation of antiretroviral therapy (ART) in patients with syphilis. Specifically, there is currently no evidence that treatment with ART needs to be delayed until treatment for syphilis has been completed. Immune reconstitution inflammatory syndrome (IRIS) in association with syphilis and treatment with ART in HIV-infected persons is uncommon.72
Monitoring and Adverse Events (Including IRIS)
Clinical and serologic responses (four-fold decrease from the titer at the time of treatment) to treatment of early-stage (primary, secondary, and early-latent) disease should be monitored at 3, 6, 9, 12, and 24 months after therapy. Serologic responses to treatment are similar in patients who are HIV infected and HIV uninfected; subtle variations can occur, however, including the temporal pattern of response.13,19,34,73
If clinical signs and symptoms persist or recur or there is a sustained four-fold increase in non-treponemal titers, treatment failure should be considered and managed per recommendations below.
After successful treatment for early syphilis (HIV-infected and -uninfected persons), 15% to 20% of patients may remain “serofast,” meaning that serum non-treponemal test titers remain reactive at a stable level, usually <1:8, for prolonged periods.19,34
This serofast state probably does not represent treatment failure. Serologic detection of potential re-infection should be based on at least a sustained four-fold increase in titer above the established serofast baseline and syphilis risk assessment.
Response to therapy for late-latent syphilis should be monitored using non-treponemal serologic tests at 6, 12, 18, and 24 months to ensure at least a four-fold decline in titer, if initially high (≥1:32), within 12 to 24 months of therapy. If clinical symptoms develop or a four-fold increase in non-treponemal titers is sustained, then treatment failure should be considered and managed per recommendations.19
The earliest CSF indicator of response to neurosyphilis treatment is a decline in CSF lymphocytosis. The CSF-VDRL may respond more slowly. If CSF pleocytosis was present initially, a CSF examination should be repeated at 6 months. Limited data suggest that changes in CSF parameters may occur more slowly in HIV-infected patients, especially those with advanced immunosuppression.14,25
If the cell count has not decreased after 6 months or if the CSF WBC is not normal after 2 years, re-treatment should be considered.
Use of ART in HIV-infected patients with syphilis has been associated with a reduced risk of serologic failure of syphilis treatment,14
a lower risk of developing neurosyphilis,14
and normalization of CSF parameters associated with decline in serum RPR titers after treatment.74
The Jarisch-Herxheimer reaction is an acute febrile reaction frequently accompanied by headache and myalgia that can occur within the first 24 hours after initiation of treatment for syphilis. Antipyretics can be used to manage symptoms but have not been proven to prevent this reaction. The Jarisch-Herxheimer reaction occurs most frequently in patients with early syphilis, high non-treponemal antibody titers, and prior penicillin treatment.75
Managing Treatment Failure
Re-treatment should be considered for patients with early-stage syphilis who
- Do not have at least a four-fold decrease in serum non-treponemal titers 6 to 12 months after treatment
- Have a sustained four-fold increase in serum non-treponemal titers after an initial four-fold decrease following treatment, or
- Have persistent or recurring clinical signs or symptoms of disease, whether as a result of treatment failure or of re-infection.
HIV-infected persons in whom treatment fails should be managed in the same manner as those who are HIV negative. Because re-infection is difficult to document and treatment failure is difficult to rule out, CSF examination and re-treatment should be considered in those who meet the previously described criteria. If CSF examination does not confirm the diagnosis of neurosyphilis, benzathine penicillin G, 2.4 million units at 1-week intervals for 3 weeks, should be administered (BIII
). Failure of non-treponemal tests to decline four-fold within 6 to 12 months after therapy for early syphilis may be indicative of treatment failure, but clinical trial data have demonstrated that regardless of HIV infection, >15% of persons with early syphilis treated with recommended therapy will not achieve the four-fold decline in non-treponemal titer used to define treatment response at 1 year.34
If titers do not respond appropriately after CSF examination and re-treatment, the value of repeated CSF examination or additional therapy is unclear, but it is generally not recommended. Person with HIV infection may be at increased risk of treatment failure, but the magnitude of these risks is not precisely defined and is likely low.19,24,57
Treatment with benzathine penicillin, 2.4 million units IM, and close clinical follow-up can be considered in patients with a four-fold increase in non-treponemal titers within the past year who are at high risk of syphilis re-infection (CIII
Patients treated for late-latent syphilis should have a CSF examination and be retreated if they develop clinical signs or symptoms of syphilis, have a sustained four-fold increase in serum non-treponemal test titer, or experience an inadequate serologic response (less than four-fold decline in an initially high [≥1:32] non-treponemal test titer) within 12 to 24 months of therapy. If CSF examination is consistent with CNS involvement, re-treatment should follow the neurosyphilis recommendations. Patients with late-latent syphilis and a normal CSF examination should be treated with benzathine penicillin 2.4 million units IM weekly for 3 doses (BIII
). As with early-stage syphilis, treatment with benzathine penicillin, 2.4 million units IM, and close clinical follow-up can be considered in patients with a four-fold increase in non-treponemal titers within the past year who are at high risk of re-infection (CIII
). Re-treatment for neurosyphilis should be considered if the CSF WBC count has not decreased 6 months after completion of treatment. Limited data suggest that changes in CSF parameters may occur more slowly in HIV-infected patients, especially those with advanced immunosuppression.25
If the cell count has not decreased after 6 months or if the CSF WBC count is not normal after 2 years, re-treatment should be considered.19
No recommendations indicate the need for secondary prophylaxis or prolonged chronic maintenance antimicrobial therapy for syphilis in HIV-infected patients. Targeted mass treatment of high-risk populations has not been demonstrated to be effective and is not recommended.76
Azithromycin is not recommended as secondary prevention because of azithromycin treatment failures reported in HIV-infected patients and reports of chromosomal mutations associated with macrolide-resistant T. pallidum
Special Considerations During Pregnancy
Pregnant women should be screened for syphilis at the first prenatal visit. Syphilis screening should be performed again early in the third trimester and at delivery in areas where syphilis prevalence is high and in women at high risk of infection and those who were previously untested.19
Syphilis screening also should be offered at sites providing episodic care to pregnant women at high risk, including emergency departments, jails, and prisons. Antepartum screening with non-treponemal testing is typical but treponemal screening is being used in some settings. Pregnant women with reactive treponemal screening tests should have reflex confirmatory testing with non-treponemal tests (see Diagnosis section above). No infant should leave the hospital without documentation of maternal syphilis-serology status determined at least once during pregnancy.77
All women who deliver stillborn infants after 20 weeks of gestation also should be tested for syphilis.
Rates of transmission to the fetus and adverse pregnancy outcomes for untreated syphilis are highest with primary, secondary, and early-latent syphilis and decrease with increasing duration of infection. Pregnancy does not appear to alter the clinical course, manifestations, or diagnostic test results for syphilis infection in adults. Concurrent syphilis infection has been associated with increased risk of perinatal transmission of HIV to the infant.78-83
Treatment of syphilis during pregnancy should consist of the same regimen recommended for HIV-infected adults who are not pregnant. Penicillin is effective for preventing maternal transmission to the fetus and for treatment of fetal infection, but current evidence is insufficient to determine the optimal penicillin regimen.84
There is some evidence to suggest that additional therapy should be considered in HIV-uninfected pregnant women with early syphilis: a second dose of benzathine penicillin G, 2.4 million units IM administered 1 week after the initial dose in women who have primary, secondary, and early-latent syphilis.19,85,86
Because of concerns about the efficacy of standard therapy in pregnant women who are not HIV infected, a second injection in 1 week should be considered for HIV-infected pregnant women (BIII
No alternatives to penicillin have been proven effective and safe for treatment of syphilis during pregnancy or for prevention of fetal infection. Pregnant women who have a history of penicillin allergy should undergo desensitization and treatment with penicillin (AIII
Erythromycin and azithromycin do not reliably cure maternal or fetal infection (AII
); tetracyclines should not be used during pregnancy because of concerns about hepatotoxicity and staining of fetal bones and teeth (AII
Data are insufficient on use of ceftriaxone88
for treatment of maternal infection and prevention of congenital syphilis (BIII
Treatment of syphilis during the second half of pregnancy may precipitate preterm labor or fetal distress if it is associated with a Jarisch-Herxheimer reaction.89
Pregnant women should be advised to seek obstetric attention after treatment if they notice contractions or a decrease in fetal movement. During the second half of pregnancy, syphilis management can be facilitated with sonographic fetal evaluation for congenital syphilis, but this evaluation should not delay therapy. Sonographic signs of fetal or placental syphilis indicate a greater risk of fetal treatment failure.90
Such cases should be managed in consultation with obstetric specialists. Evidence is insufficient to recommend specific regimens for these situations. After >20 weeks of gestation, fetal and contraction monitoring for 24 hours after initiation of treatment for early syphilis should be considered when sonographic findings indicate fetal infection.
Repeat serologic titers should be performed in the third trimester and at delivery for women treated for syphilis during pregnancy. Data are insufficient on the non-treponemal serologic response to syphilis after stage-appropriate therapy in HIV-infected pregnant women. Non-treponemal titers can be assessed monthly in women at high risk of re-infection. Clinical and non-treponemal antibody titers should be appropriate for the stage of disease, although most women will deliver before their serologic response can be definitively assessed. Maternal treatment is likely to be inadequate if delivery occurs within 30 days of therapy, if a woman has clinical signs of infection at delivery, or if the maternal antibody titer is four-fold higher than the pre-treatment titer.19
Recommendations for Treating Treponema pallidum Infections (Syphilis) Preventing Infection
|Empiric treatment of incubating syphilis is recommended to prevent the development of disease in those who are sexually exposed.
Indication for Treatment:
- An individual who was exposed sexually within 90 days preceding the diagnosis of primary, secondary, or early-latent syphilis in a sex partner (AII)
- Individuals exposed >90 days before syphilis diagnosis in a sex partner, if serologic test results are not available immediately and the opportunity for follow-up is uncertain (AIII).
- Same as for early stage syphilis listed below
|General Considerations for Treating Syphilis:
- The efficacy of non-penicillin alternatives has not been well evaluated in HIV-infected persons and should be undertaken only with close clinical and serologic monitoring.
- The Jarisch-Herxheimer reaction is an acute febrile reaction accompanied by headache and myalgias that can occur within the first 24 hours after therapy for early syphilis.
|Treatment Recommendations Depending on Stage of Disease:
Early Stage (Primary, Secondary, and Early-Latent Syphilis)
Alternative Therapy (For Penicillin-Allergic Patients):
- Benzathine penicillin G 2.4 million units IM for 1 dose (AII)
- Doxycycline 100 mg PO BID for 14 days (BII), or
- Ceftriaxone 1 g IM or IV daily for 10-14 days (BII), or
- Azithromycin 2 g PO for 1 dose (BII)
Note: Chromosomal mutations associated with azithromycin resistance and treatment failures have been reported. Azithromycin should be used with caution only when treatment with penicillin or doxycycline is not feasible. Azithromycin is not recommended for MSM or pregnant women (AII)
Note: Patients with penicillin allergy whose compliance or follow-up cannot be ensured should be desensitized and treated with benzathine penicillin
Late-Latent Disease (>1 year or Of Unknown Duration, and No Sign of Neurosyphilis)
Alternative Therapy (For Penicillin-Allergic Patients):
- Benzathine penicillin G 2.4 million units IM weekly for 3 doses (AII)
Note: Patients with penicillin allergy whose compliance or follow-up cannot be ensured should be desensitized and treated with benzathine penicillin
- Doxycycline 100 mg PO BID for 28 days (BIII)
Late-Stage (Tertiary—Cardiovascular or Gummatous Disease)
- Perform CSF examination to rule out neurosyphilis and obtain infectious diseases consultation to guide management
Neurosyphilis, Otic, or Ocular Disease
- Benzathine penicillin G 2.4 million units IM weekly for 3 doses (AII)
- Aqueous crystalline penicillin G, 18–24 million units per day, administered as 3–4 million units IV q4h or by continuous IV infusion for 10–14 days (AII) +/- benzathine penicillin G 2.4 million units IM weekly for 3 doses after completion of IV therapy (CIII)
For Penicillin-Allergic Patients:
- Procaine penicillin G 2.4 million units IM daily plus probenecid 500 mg PO QID for 10–14 days (BII) +/- benzathine penicillin G 2.4 million units IM weekly for 3 doses after completion of above (CIII)
- Patients who are allergic to sulfa-containing medications should not be given probenecid, thus the procaine penicillin regimen is not recommended for these patients (AIII).
- Desensitization to penicillin is the preferred approach; if not feasible, ceftriaxone 2 g IM or IV daily for 10–14 days (BII)
- Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sexually transmitted infections. Feb 1999;75(1):3-17. Available at http://www.ncbi.nlm.nih.gov/pubmed/10448335.
- Rottingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis. Oct 2001;28(10):579-597. Available at http://www.ncbi.nlm.nih.gov/pubmed/11689757.
- Blocker ME, Levine WC, St Louis ME. HIV prevalence in patients with syphilis, United States. Sex Transm Dis. Jan 2000;27(1):53-59. Available at http://www.ncbi.nlm.nih.gov/pubmed/10654870.
- Torian LV, Makki HA, Menzies IB, Murrill CS, Weisfuse IB. HIV infection in men who have sex with men, New York City Department of Health sexually transmitted disease clinics, 1990-1999: a decade of serosurveillance finds that racial disparities and associations between HIV and gonorrhea persist. Sex Transm Dis. Feb 2002;29(2):73-78. Available at http://www.ncbi.nlm.nih.gov/pubmed/11818891.
- Stolte IG, Dukers NH, de Wit JB, Fennema JS, Coutinho RA. Increase in sexually transmitted infections among homosexual men in Amsterdam in relation to HAART. Sexually transmitted infections. Jun 2001;77(3):184-186. Available at http://www.ncbi.nlm.nih.gov/pubmed/11402225.
- Peterman TA, Heffelfinger JD, Swint EB, Groseclose SL. The changing epidemiology of syphilis. Sex Transm Dis. Oct 2005;32(10 Suppl):S4-10. Available at http://www.ncbi.nlm.nih.gov/pubmed/16205291.
- Paz-Bailey G, Meyers A, Blank S, et al. A case-control study of syphilis among men who have sex with men in New York City: association With HIV infection. Sex Transm Dis. Oct 2004;31(10):581-587. Available at http://www.ncbi.nlm.nih.gov/pubmed/15388994.
- Centers for Disease C, Prevention. Outbreak of syphilis among men who have sex with men--Southern California, 2000. MMWR Morb Mortal Wkly Rep. Feb 23 2001;50(7):117-120. Available at http://www.ncbi.nlm.nih.gov/pubmed/11393490.
- Calza L, Manfredi R, Marinacci G, Tadolini M, Fortunato L, Chiodo F. Efficacy of penicillin G benzathine as antimicrobial treatment of cutaneous secondary syphilis in patients with HIV infection. Journal of chemotherapy. Oct 2002;14(5):533-534. Available at http://www.ncbi.nlm.nih.gov/pubmed/12462435.
- Rompalo AM, Lawlor J, Seaman P, Quinn TC, Zenilman JM, Hook EW, 3rd. Modification of syphilitic genital ulcer manifestations by coexistent HIV infection. Sex Transm Dis. Aug 2001;28(8):448-454. Available at http://www.ncbi.nlm.nih.gov/pubmed/11473216.
- Musher DM, Hamill RJ, Baughn RE. Effect of human immunodeficiency virus (HIV) infection on the course of syphilis and on the response to treatment. Ann Intern Med. Dec 1 1990;113(11):872-881. Available at http://www.ncbi.nlm.nih.gov/pubmed/2240901.
- Radolf JD, Kaplan RP. Unusual manifestations of secondary syphilis and abnormal humoral immune response to Treponema pallidum antigens in a homosexual man with asymptomatic human immunodeficiency virus infection. Journal of the American Academy of Dermatology. Feb 1988;18(2 Pt 2):423-428. Available at http://www.ncbi.nlm.nih.gov/pubmed/2963840.
- Ghanem KG, Workowski KA. Management of adult syphilis. Clin Infect Dis. Dec 2011;53 Suppl 3:S110-128. Available at http://www.ncbi.nlm.nih.gov/pubmed/22080265.
- Ghanem KG, Moore RD, Rompalo AM, Erbelding EJ, Zenilman JM, Gebo KA. Neurosyphilis in a clinical cohort of HIV-1-infected patients. AIDS. Jun 19 2008;22(10):1145-1151. Available at http://www.ncbi.nlm.nih.gov/pubmed/18525260.
- Centers for Disease C, Prevention. Symptomatic early neurosyphilis among HIV-positive men who have sex with men--four cities, United States, January 2002-June 2004. MMWR Morb Mortal Wkly Rep. Jun 29 2007;56(25):625-628. Available at http://www.ncbi.nlm.nih.gov/pubmed/17597693.
- Buchacz K, Patel P, Taylor M, et al. Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections. AIDS. Oct 21 2004;18(15):2075-2079. Available at http://www.ncbi.nlm.nih.gov/pubmed/15577629.
- Modjarrad K, Vermund SH. Effect of treating co-infections on HIV-1 viral load: a systematic review. Lancet Infect Dis. Jul 2010;10(7):455-463. Available at http://www.ncbi.nlm.nih.gov/pubmed/20610327.
- Palacios R, Jimenez-Onate F, Aguilar M, et al. Impact of syphilis infection on HIV viral load and CD4 cell counts in HIV-infected patients. J Acquir Immune Defic Syndr. Mar 1 2007;44(3):356-359. Available at http://www.ncbi.nlm.nih.gov/pubmed/17159654.
- Workowski KA, Berman S, Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. Dec 17 2010;59(RR-12):1-110. Available at http://www.ncbi.nlm.nih.gov/pubmed/21160459.
- Kofoed K, Gerstoft J, Mathiesen LR, Benfield T. Syphilis and human immunodeficiency virus (HIV)-1 coinfection: influence on CD4 T-cell count, HIV-1 viral load, and treatment response. Sex Transm Dis. Mar 2006;33(3):143-148. Available at http://www.ncbi.nlm.nih.gov/pubmed/16505739.
- Rompalo AM, Joesoef MR, O'Donnell JA, et al. Clinical manifestations of early syphilis by HIV status and gender: results of the syphilis and HIV study. Sex Transm Dis. Mar 2001;28(3):158-165. Available at http://www.ncbi.nlm.nih.gov/pubmed/11289198.
- Dourmishev LA, Popov JM, Rusinova D. Paraneoplastic dermatomyositis associated with testicular cancer: a case report and literature review. Acta Dermatovenerol Alp Panonica Adriat. 2010;19(1):39-43. Available at http://www.ncbi.nlm.nih.gov/pubmed/20372774.
- Bayne LL, Schmidley JW, Goodin DS. Acute syphilitic meningitis. Its occurrence after clinical and serologic cure of secondary syphilis with penicillin G. Arch Neurol. Feb 1986;43(2):137-138. Available at http://www.ncbi.nlm.nih.gov/pubmed/3947251.
- Berry CD, Hooton TM, Collier AC, Lukehart SA. Neurologic relapse after benzathine penicillin therapy for secondary syphilis in a patient with HIV infection. N Engl J Med. Jun 18 1987;316(25):1587-1589. Available at http://www.ncbi.nlm.nih.gov/pubmed/3587291.
- Marra CM, Maxwell CL, Smith SL, et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis. Feb 1 2004;189(3):369-376. Available at http://www.ncbi.nlm.nih.gov/pubmed/14745693.
- Marra CM, Maxwell CL, Tantalo L, et al. Normalization of cerebrospinal fluid abnormalities after neurosyphilis therapy: does HIV status matter? Clin Infect Dis. Apr 1 2004;38(7):1001-1006. Available at http://www.ncbi.nlm.nih.gov/pubmed/15034833.
- Biotti D, Bidot S, Mahy S, et al. Ocular syphilis and HIV infection. Sex Transm Dis. Jan 2010;37(1):41-43. Available at http://www.ncbi.nlm.nih.gov/pubmed/20118676.
- Tucker JD, Li JZ, Robbins GK, et al. Ocular syphilis among HIV-infected patients: a systematic analysis of the literature. Sexually transmitted infections. Feb 2011;87(1):4-8. Available at http://www.ncbi.nlm.nih.gov/pubmed/20798396.
- Wicher K, Horowitz HW, Wicher V. Laboratory methods of diagnosis of syphilis for the beginning of the third millennium. Microbes and infection / Institut Pasteur. Oct 1999;1(12):1035-1049. Available at http://www.ncbi.nlm.nih.gov/pubmed/10617935.
- Centers for Disease C, Prevention. Discordant results from reverse sequence syphilis screening--five laboratories, United States, 2006-2010. MMWR Morb Mortal Wkly Rep. Feb 11 2011;60(5):133-137. Available at http://www.ncbi.nlm.nih.gov/pubmed/21307823.
- Centers for Disease C, Prevention. Syphilis testing algorithms using treponemal tests for initial screening--four laboratories, New York City, 2005-2006. MMWR Morb Mortal Wkly Rep. Aug 15 2008;57(32):872-875. Available at http://www.ncbi.nlm.nih.gov/pubmed/18701877.
- Wohrl S, Geusau A. Neurosyphilis is unlikely in patients with late latent syphilis and a negative blood VDRL-test. Acta Derm Venereol. 2006;86(4):335-339. Available at http://www.ncbi.nlm.nih.gov/pubmed/16874420.
- Rompalo AM, Cannon RO, Quinn TC, Hook EW, 3rd. Association of biologic false-positive reactions for syphilis with human immunodeficiency virus infection. J Infect Dis. Jun 1992;165(6):1124-1126. Available at http://www.ncbi.nlm.nih.gov/pubmed/1583332.
- Rolfs RT, Joesoef MR, Hendershot EF, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med. Jul 31 1997;337(5):307-314. Available at http://www.ncbi.nlm.nih.gov/pubmed/9235493.
- Augenbraun MH, DeHovitz JA, Feldman J, Clarke L, Landesman S, Minkoff HM. Biological false-positive syphilis test results for women infected with human immunodeficiency virus. Clin Infect Dis. Dec 1994;19(6):1040-1044. Available at http://www.ncbi.nlm.nih.gov/pubmed/7888531.
- Hicks CB, Benson PM, Lupton GP, Tramont EC. Seronegative secondary syphilis in a patient infected with the human immunodeficiency virus (HIV) with Kaposi sarcoma. A diagnostic dilemma. Ann Intern Med. Oct 1987;107(4):492-495. Available at http://www.ncbi.nlm.nih.gov/pubmed/3307583.
- Kingston AA, Vujevich J, Shapiro M, et al. Seronegative secondary syphilis in 2 patients coinfected with human immunodeficiency virus. Archives of dermatology. Apr 2005;141(4):431-433. Available at http://www.ncbi.nlm.nih.gov/pubmed/15837859.
- Augenbraun M, Rolfs R, Johnson R, Joesoef R, Pope V. Treponemal specific tests for the serodiagnosis of syphilis. Syphilis and HIV Study Group. Sex Transm Dis. Nov 1998;25(10):549-552. Available at http://www.ncbi.nlm.nih.gov/pubmed/9858352.
- Libois A, De Wit S, Poll B, et al. HIV and syphilis: when to perform a lumbar puncture. Sex Transm Dis. Mar 2007;34(3):141-144. Available at http://www.ncbi.nlm.nih.gov/pubmed/16865051.
- Ghanem KG. Sensitivity and specificity of lumbar puncture in HIV-infected patients with syphilis and no neurologic symptoms reply. Clin Infect Dis. 2009;49:162-163. Available at
- Marra CM. Deja vu all over again: when to perform a lumbar puncture in HIV-infected patients with syphilis. Sex Transm Dis. Mar 2007;34(3):145-146. Available at http://www.ncbi.nlm.nih.gov/pubmed/17325601.
- Jaffe HW, Larsen SA, Peters M, Jove DF, Lopez B, Schroeter AL. Tests for treponemal antibody in CSF. Arch Intern Med. Feb 1978;138(2):252-255. Available at http://www.ncbi.nlm.nih.gov/pubmed/343742.
- Rietmeijer CA. Risk reduction counselling for prevention of sexually transmitted infections: how it works and how to make it work. Sexually transmitted infections. Feb 2007;83(1):2-9. Available at http://www.ncbi.nlm.nih.gov/pubmed/17283359.
- Force USPST. Behavioral counseling to prevent sexually transmitted infections: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. Oct 7 2008;149(7):491-496, W495. Available at http://www.ncbi.nlm.nih.gov/pubmed/18838729.
- Kamb ML, Fishbein M, Douglas JM, Jr., et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA. Oct 7 1998;280(13):1161-1167. Available at http://www.ncbi.nlm.nih.gov/pubmed/9777816.
- Richardson JL, Milam J, Stoyanoff S, et al. Using patient risk indicators to plan prevention strategies in the clinical care setting. J Acquir Immune Defic Syndr. Oct 1 2004;37 Suppl 2:S88-94. Available at http://www.ncbi.nlm.nih.gov/pubmed/15385904.
- Fisher JD, Cornman DH, Osborn CY, Amico KR, Fisher WA, Friedland GA. Clinician-initiated HIV risk reduction intervention for HIV-positive persons: Formative Research, Acceptability, and Fidelity of the Options Project. J Acquir Immune Defic Syndr. Oct 1 2004;37 Suppl 2:S78-87. Available at http://www.ncbi.nlm.nih.gov/pubmed/15385903.
- Branger J, van der Meer JT, van Ketel RJ, Jurriaans S, Prins JM. High incidence of asymptomatic syphilis in HIV-infected MSM justifies routine screening. Sex Transm Dis. Feb 2009;36(2):84-85. Available at http://www.ncbi.nlm.nih.gov/pubmed/18971797.
- Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. Sep 1 2009;49(5):651-681. Available at http://www.ncbi.nlm.nih.gov/pubmed/19640227.
- Centers for Disease C, Prevention, Health R, et al. Recommendations for incorporating human immunodeficiency virus (HIV) prevention into the medical care of persons living with HIV. Clin Infect Dis. Jan 1 2004;38(1):104-121. Available at http://www.ncbi.nlm.nih.gov/pubmed/14679456.
- Centers for Disease C, Prevention. Recommendations for partner services programs for HIV infection, syphilis, gonorrhea, and chlamydial infection. MMWR Recomm Rep. Nov 7 2008;57(RR-9):1-83; quiz CE81-84. Available at http://www.ncbi.nlm.nih.gov/pubmed/18987617.
- Moore MB, Jr., Price EV, Knox JM, Elgin LW. Epidemiologic Treatment of Contacts to Infectious Syphilis. Public Health Rep. Nov 1963;78:966-970. Available at http://www.ncbi.nlm.nih.gov/pubmed/14084872.
- Schroeter AL, Turner RH, Lucas JB, Brown WJ. Therapy for incubating syphilis. Effectiveness of gonorrhea treatment. JAMA. Nov 1 1971;218(5):711-713. Available at http://www.ncbi.nlm.nih.gov/pubmed/5171497.
- Schober PC, Gabriel G, White P, Felton WF, Thin RN. How infectious is syphilis? Br J Vener Dis. Aug 1983;59(4):217-219. Available at http://www.ncbi.nlm.nih.gov/pubmed/6871650.
- Hook EW, 3rd, Marra CM. Acquired syphilis in adults. N Engl J Med. Apr 16 1992;326(16):1060-1069. Available at http://www.ncbi.nlm.nih.gov/pubmed/1549153.
- Malone JL, Wallace MR, Hendrick BB, et al. Syphilis and neurosyphilis in a human immunodeficiency virus type-1 seropositive population: evidence for frequent serologic relapse after therapy. Am J Med. Jul 1995;99(1):55-63. Available at http://www.ncbi.nlm.nih.gov/pubmed/7598143.
- Walter T, Lebouche B, Miailhes P, et al. Symptomatic relapse of neurologic syphilis after benzathine penicillin G therapy for primary or secondary syphilis in HIV-infected patients. Clin Infect Dis. Sep 15 2006;43(6):787-790. Available at http://www.ncbi.nlm.nih.gov/pubmed/16912958.
- Ghanem KG, Erbelding EJ, Cheng WW, Rompalo AM. Doxycycline compared with benzathine penicillin for the treatment of early syphilis. Clin Infect Dis. Mar 15 2006;42(6):e45-49. Available at http://www.ncbi.nlm.nih.gov/pubmed/16477545.
- Wong T, Singh AE, De P. Primary syphilis: serological treatment response to doxycycline/tetracycline versus benzathine penicillin. Am J Med. Oct 2008;121(10):903-908. Available at http://www.ncbi.nlm.nih.gov/pubmed/18823862.
- Hook EW, 3rd, Roddy RE, Handsfield HH. Ceftriaxone therapy for incubating and early syphilis. J Infect Dis. Oct 1988;158(4):881-884. Available at http://www.ncbi.nlm.nih.gov/pubmed/3171231.
- Kiddugavu MG, Kiwanuka N, Wawer MJ, et al. Effectiveness of syphilis treatment using azithromycin and/or benzathine penicillin in Rakai, Uganda. Sex Transm Dis. Jan 2005;32(1):1-6. Available at http://www.ncbi.nlm.nih.gov/pubmed/15614114.
- Riedner G, Rusizoka M, Todd J, et al. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N Engl J Med. Sep 22 2005;353(12):1236-1244. Available at http://www.ncbi.nlm.nih.gov/pubmed/16177249.
- Hook EW, 3rd, Behets F, Van Damme K, et al. A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis. J Infect Dis. Jun 1 2010;201(11):1729-1735. Available at http://www.ncbi.nlm.nih.gov/pubmed/20402591.
- Centers for Disease C, Prevention. Azithromycin treatment failures in syphilis infections--San Francisco, California, 2002-2003. MMWR Morb Mortal Wkly Rep. Mar 12 2004;53(9):197-198. Available at http://www.ncbi.nlm.nih.gov/pubmed/15017376.
- Lukehart SA, Godornes C, Molini BJ, et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med. Jul 8 2004;351(2):154-158. Available at http://www.ncbi.nlm.nih.gov/pubmed/15247355.
- Mitchell SJ, Engelman J, Kent CK, Lukehart SA, Godornes C, Klausner JD. Azithromycin-resistant syphilis infection: San Francisco, California, 2000-2004. Clin Infect Dis. Feb 1 2006;42(3):337-345. Available at http://www.ncbi.nlm.nih.gov/pubmed/16392078.
- Martin IE, Tsang RS, Sutherland K, et al. Molecular characterization of syphilis in patients in Canada: azithromycin resistance and detection of Treponema pallidum DNA in whole-blood samples versus ulcerative swabs. J Clin Microbiol. Jun 2009;47(6):1668-1673. Available at http://www.ncbi.nlm.nih.gov/pubmed/19339468.
- Wu H, Chang SY, Lee NY, et al. Evaluation of macrolide resistance and enhanced molecular typing of Treponema pallidum in patients with syphilis in Taiwan: a prospective multicenter study. J Clin Microbiol. Jul 2012;50(7):2299-2304. Available at http://www.ncbi.nlm.nih.gov/pubmed/22518868.
- Chen CY, Chi KH, Pillay A, Nachamkin E, Su JR, Ballard RC. Detection of the A2058G and A2059G 23S rRNA Gene Point Mutations Associated with Azithromycin Resistance in Treponema pallidum by Use of a TaqMan Real-Time Multiplex PCR Assay. J Clin Microbiol. Mar 2013;51(3):908-913. Available at http://www.ncbi.nlm.nih.gov/pubmed/23284026.
- Dowell ME, Ross PG, Musher DM, Cate TR, Baughn RE. Response of latent syphilis or neurosyphilis to ceftriaxone therapy in persons infected with human immunodeficiency virus. Am J Med. Nov 1992;93(5):481-488. Available at http://www.ncbi.nlm.nih.gov/pubmed/1442850.
- Smith NH, Musher DM, Huang DB, et al. Response of HIV-infected patients with asymptomatic syphilis to intensive intramuscular therapy with ceftriaxone or procaine penicillin. Int J STD AIDS. May 2004;15(5):328-332. Available at http://www.ncbi.nlm.nih.gov/pubmed/15117503.
- Bernal E, Munoz A, Ortiz Mdel M, Cano A. [Syphilitic panuveitis in an HIV-infected patient after immune restoration]. Enferm Infecc Microbiol Clin. Oct 2009;27(8):487-489. Available at http://www.ncbi.nlm.nih.gov/pubmed/19406524.
- Long CM, Klausner JD, Leon S, et al. Syphilis treatment and HIV infection in a population-based study of persons at high risk for sexually transmitted disease/HIV infection in Lima, Peru. Sex Transm Dis. Mar 2006;33(3):151-155.Available at http://www.ncbi.nlm.nih.gov/pubmed/16508525.
- Marra CM, Maxwell CL, Tantalo LC, Sahi SK, Lukehart SA. Normalization of serum rapid plasma reagin titer predicts normalization of cerebrospinal fluid and clinical abnormalities after treatment of neurosyphilis. Clin Infect Dis. Oct 1 2008;47(7):893-899. Available at http://www.ncbi.nlm.nih.gov/pubmed/18715154.
- Yang CJ, Lee NY, Lin YH, et al. Jarisch-Herxheimer reaction after penicillin therapy among patients with syphilis in the era of the hiv infection epidemic: incidence and risk factors. Clin Infect Dis. Oct 15 2010;51(8):976-979. Available at http://www.ncbi.nlm.nih.gov/pubmed/20825309.
- Rekart ML, Patrick DM, Chakraborty B, et al. Targeted mass treatment for syphilis with oral azithromycin. Lancet. Jan 25 2003;361(9354):313-314. Available at http://www.ncbi.nlm.nih.gov/pubmed/12559870.
- Genc M, Ledger WJ. Syphilis in pregnancy. Sexually transmitted infections. Apr 2000;76(2):73-79. Available at http://www.ncbi.nlm.nih.gov/pubmed/10858706.
- Berman SM. Maternal syphilis: pathophysiology and treatment. Bulletin of the World Health Organization. Jun 2004;82(6):433-438. Available at http://www.ncbi.nlm.nih.gov/pubmed/15356936.
- Tess BH, Rodrigues LC, Newell ML, Dunn DT, Lago TD. Breastfeeding, genetic, obstetric and other risk factors associated with mother-to-child transmission of HIV-1 in Sao Paulo State, Brazil. Sao Paulo Collaborative Study for Vertical Transmission of HIV-1. AIDS. Mar 26 1998;12(5):513-520. Available at http://www.ncbi.nlm.nih.gov/pubmed/9543450.
- Lee MJ, Hallmark RJ, Frenkel LM, Del Priore G. Maternal syphilis and vertical perinatal transmission of human immunodeficiency virus type-1 infection. Int J Gynaecol Obstet. Dec 1998;63(3):247-252. Available at http://www.ncbi.nlm.nih.gov/pubmed/9989893.
- Wendel GD, Jr., Sheffield JS, Hollier LM, Hill JB, Ramsey PS, Sanchez PJ. Treatment of syphilis in pregnancy and prevention of congenital syphilis. Clin Infect Dis. Oct 15 2002;35(Suppl 2):S200-209. Available at http://www.ncbi.nlm.nih.gov/pubmed/12353207.
- Kreitchmann R, Fuchs SC, Suffert T, Preussler G. Perinatal HIV-1 transmission among low income women participants in the HIV/AIDS Control Program in Southern Brazil: a cohort study. BJOG. Jun 2004;111(6):579-584. Available at http://www.ncbi.nlm.nih.gov/pubmed/15198786.
- Mwapasa V, Rogerson SJ, Kwiek JJ, et al. Maternal syphilis infection is associated with increased risk of mother-to-child transmission of HIV in Malawi. AIDS. Sep 11 2006;20(14):1869-1877. Available at http://www.ncbi.nlm.nih.gov/pubmed/16954728.
- Walker GJ. Antibiotics for syphilis diagnosed during pregnancy. Cochrane Database Syst Rev. 2001(3):CD001143. Available at http://www.ncbi.nlm.nih.gov/pubmed/11686978.
- Donders GG, Desmyter J, Hooft P, Dewet GH. Apparent failure of one injection of benzathine penicillin G for syphilis during pregnancy in human immunodeficiency virus-seronegative African women. Sex Transm Dis. Feb 1997;24(2):94-101. Available at http://www.ncbi.nlm.nih.gov/pubmed/9111755.
- Sheffield JS, Sanchez PJ, Morris G, et al. Congenital syphilis after maternal treatment for syphilis during pregnancy. Am J Obstet Gynecol. Mar 2002;186(3):569-573. Available at http://www.ncbi.nlm.nih.gov/pubmed/11904625.
- Ramsey PS, Vaules MB, Vasdev GM, Andrews WW, Ramin KD. Maternal and transplacental pharmacokinetics of azithromycin. Am J Obstet Gynecol. Mar 2003;188(3):714-718. Available at http://www.ncbi.nlm.nih.gov/pubmed/12634646.
- Zhou P, Gu Z, Xu J, Wang X, Liao K. A study evaluating ceftriaxone as a treatment agent for primary and secondary syphilis in pregnancy. Sex Transm Dis. 2005; 32(8):495-498. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16041252.
- Klein VR, Cox SM, Mitchell MD, Wendel GD, Jr. The Jarisch-Herxheimer reaction complicating syphilotherapy in pregnancy. Obstet Gynecol. Mar 1990;75(3 Pt 1):375-380. Available at http://www.ncbi.nlm.nih.gov/pubmed/2304710.
- Hollier LM, Harstad TW, Sanchez PJ, Twickler DM, Wendel GD, Jr. Fetal syphilis: clinical and laboratory characteristics. Obstet Gynecol. Jun 2001;97(6):947-953. Available at http://www.ncbi.nlm.nih.gov/pubmed/11384701.